Surgery Partners, Inc. (NASDAQ:SGRY) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in shares of Surgery Partners, Inc. (NASDAQ:SGRY - Free Report) by 4.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 555,154 shares of the company's stock after selling 23,394 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.44% of Surgery Partners worth $11,753,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of SGRY. KBC Group NV grew its holdings in Surgery Partners by 66.1% during the fourth quarter. KBC Group NV now owns 3,962 shares of the company's stock valued at $84,000 after purchasing an additional 1,577 shares during the period. State of Wyoming lifted its position in shares of Surgery Partners by 94.4% during the 4th quarter. State of Wyoming now owns 4,002 shares of the company's stock valued at $85,000 after buying an additional 1,943 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Surgery Partners by 12.1% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,296 shares of the company's stock valued at $91,000 after acquiring an additional 465 shares during the period. MeadowBrook Investment Advisors LLC increased its holdings in Surgery Partners by 16.6% in the 4th quarter. MeadowBrook Investment Advisors LLC now owns 10,280 shares of the company's stock worth $218,000 after acquiring an additional 1,460 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Surgery Partners by 279.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,762 shares of the company's stock worth $228,000 after acquiring an additional 7,925 shares during the period.

Insiders Place Their Bets

In other news, CFO David T. Doherty sold 6,733 shares of Surgery Partners stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $24.02, for a total value of $161,726.66. Following the completion of the transaction, the chief financial officer now owns 150,868 shares in the company, valued at approximately $3,623,849.36. This trade represents a 4.27% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Marissa Brittenham sold 3,156 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $24.09, for a total transaction of $76,028.04. Following the completion of the sale, the insider now directly owns 63,408 shares in the company, valued at approximately $1,527,498.72. This represents a 4.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.30% of the stock is currently owned by company insiders.

Surgery Partners Stock Performance

Shares of SGRY traded down $0.22 during trading hours on Wednesday, reaching $23.06. 2,412,158 shares of the company traded hands, compared to its average volume of 1,110,304. The company has a quick ratio of 1.66, a current ratio of 1.80 and a debt-to-equity ratio of 0.99. The business has a fifty day moving average price of $22.29 and a 200-day moving average price of $22.75. Surgery Partners, Inc. has a 12-month low of $19.50 and a 12-month high of $33.97. The stock has a market capitalization of $2.96 billion, a P/E ratio of -48.04, a P/E/G ratio of 19.21 and a beta of 1.96.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). The firm had revenue of $776.00 million during the quarter, compared to analysts' expectations of $777.77 million. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. The company's revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.10 earnings per share. Equities analysts anticipate that Surgery Partners, Inc. will post 0.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on SGRY shares. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $35.00 price objective on shares of Surgery Partners in a research note on Tuesday, March 25th. Barclays dropped their price target on Surgery Partners from $25.00 to $24.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 27th. Benchmark reissued a "buy" rating and issued a $35.00 target price on shares of Surgery Partners in a report on Monday, April 21st. Finally, Macquarie dropped their target price on shares of Surgery Partners from $34.00 to $33.00 and set an "outperform" rating for the company in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Surgery Partners presently has an average rating of "Moderate Buy" and an average price target of $33.56.

Surgery Partners Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.